Cerebrolysin Reduced Anxiety After Traumatic Brain Injury in Trial Analysis
A peptide brain therapy (Cerebrolysin) significantly reduced anxiety after traumatic brain injury with a large effect size of 0.73 compared to placebo.
Quick Facts
What This Study Found
Cerebrolysin, a peptide preparation derived from pig brain tissue, significantly reduced anxiety in patients with moderate and severe traumatic brain injury (TBI) compared to placebo. Statistically significant differences in HADS-Anxiety scores were found at both the second and third follow-up visits, with a large effect size of 0.73.
The study also identified correlations between anxiety/depression scores and other neuropsychological measures, suggesting that post-TBI mental health is connected to cognitive and motor recovery. The patient sample had a mean age of 45.3, was primarily male, and had a 24-hour Glasgow Coma Scale mean of 12.67 (indicating moderate-to-severe injury).
Key Numbers
n=125 · Effect size 0.73 (large) for anxiety · Mean age 45.3 · GCS mean 12.67 · Significant at visits 2 and 3 · HADS-Anxiety/Depression assessed
How They Did This
This was a secondary retrospective analysis of the CAPTAIN II trial data. 125 TBI patients with moderate and severe disability were divided into two groups: Cerebrolysin treatment and saline placebo. Researchers used the Hospital Anxiety and Depression Scale (HADS) to measure psychiatric outcomes, Spearman's correlations to assess relationships between HADS and other neuropsychological scales, and Mann-Whitney U tests to compare anxiety and depression scores between treatment groups.
Why This Research Matters
Traumatic brain injury frequently causes depression, anxiety, and cognitive impairment that persist long after the initial injury. There are few treatments specifically designed for post-TBI psychiatric symptoms. The finding that Cerebrolysin — already used in some countries for neurological recovery — could significantly reduce post-TBI anxiety with a large effect size suggests it may address both the neurological and psychiatric consequences of brain injury.
The Bigger Picture
Cerebrolysin is one of the few neurotrophic peptide preparations that has reached clinical use (approved in over 40 countries, though not in the US). This analysis adds psychiatric outcomes to its evidence base, which has primarily focused on cognitive recovery. The connection between anxiety, depression, and cognitive function after TBI reinforces the idea that effective neurological recovery requires addressing mental health simultaneously — and that neuropeptide therapies may help on both fronts.
What This Study Doesn't Tell Us
This is a retrospective secondary analysis, not a prospectively designed psychiatric outcomes trial. The sample of 125 patients is moderate in size. The analysis was conducted post-hoc on an existing database, increasing the risk of finding spurious associations. The authors explicitly note that confirmatory trials are needed. Cerebrolysin is not FDA-approved and its mechanisms remain debated.
Questions This Raises
- ?Would a prospectively designed trial specifically targeting post-TBI anxiety confirm these findings?
- ?Does Cerebrolysin's effect on anxiety persist long-term, or does it diminish after treatment ends?
- ?Could Cerebrolysin benefit patients with mild TBI who also develop anxiety and cognitive symptoms?
Trust & Context
- Key Stat:
- 0.73 effect size on anxiety Cerebrolysin produced a large effect size (0.73) for anxiety reduction — considered clinically meaningful — in moderate-to-severe TBI patients
- Evidence Grade:
- This is a moderate-grade study: a secondary retrospective analysis of a placebo-controlled trial. While the original CAPTAIN II trial was well-designed, this specific analysis was post-hoc and the authors explicitly call for confirmatory trials.
- Study Age:
- Published in 2022, this is a recent analysis that adds to the growing evidence base for Cerebrolysin in TBI. The parent CAPTAIN II trial data provides a robust foundation, though the psychiatric outcomes were not the primary study endpoint.
- Original Title:
- The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis.
- Published In:
- Medicina (Kaunas, Lithuania), 58(5) (2022)
- Authors:
- Mureșanu, Ioana Anamaria, Grad, Diana Alecsandra, Mureșanu, Dafin Fior, Hapca, Elian, Benedek, Irina, Jemna, Nicoleta, Strilciuc, Ștefan, Popescu, Bogdan Ovidiu, Perju-Dumbravă, Lăcrămioara, Cherecheș, Răzvan Mircea
- Database ID:
- RPEP-06384
Evidence Hierarchy
Frequently Asked Questions
What is Cerebrolysin and how might it help after brain injury?
Cerebrolysin is an injectable preparation containing small peptides and amino acids derived from pig brain tissue. It's thought to mimic natural brain growth factors (neurotrophins) that help neurons survive and recover after injury. It's approved for neurological conditions in over 40 countries but not in the US.
Why do brain injuries cause anxiety and depression?
Brain injury damages neural circuits involved in emotion regulation, disrupts neurotransmitter balance, and triggers inflammation that affects mood-related brain regions. Additionally, the psychological impact of sudden disability, cognitive impairment, and lifestyle disruption contributes to psychiatric symptoms. Up to 50% of TBI patients develop significant anxiety or depression.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06384APA
Mureșanu, Ioana Anamaria; Grad, Diana Alecsandra; Mureșanu, Dafin Fior; Hapca, Elian; Benedek, Irina; Jemna, Nicoleta; Strilciuc, Ștefan; Popescu, Bogdan Ovidiu; Perju-Dumbravă, Lăcrămioara; Cherecheș, Răzvan Mircea. (2022). The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis.. Medicina (Kaunas, Lithuania), 58(5). https://doi.org/10.3390/medicina58050648
MLA
Mureșanu, Ioana Anamaria, et al. "The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis.." Medicina (Kaunas, 2022. https://doi.org/10.3390/medicina58050648
RethinkPeptides
RethinkPeptides Research Database. "The Effect of Cerebrolysin on Anxiety, Depression, and Cogni..." RPEP-06384. Retrieved from https://rethinkpeptides.com/research/muresanu-2022-the-effect-of-cerebrolysin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.